The molecular markers for prognostic evaluation of areca-associated buccal squamous cell carcinoma.
BACKGROUND
Buccal squamous cell carcinoma (BSCC) is the most frequently occurring oral cancer in Asians due to the popularity of areca use in this area. The aim of the present study was to evaluate the survival of areca-associated BSCC associated with multiple molecular markers.


METHODS
Using immunohistochemistry, we evaluated the survival of a cohort of 55 patients with BSCC being followed long term, as correlated to the expression of variable markers.


RESULTS
We found that p53, p21, Rb, cyclin D1 (CCD1), MDM2, and gamma-catenin were positive in 81, 60, 70, 31, 88, and 44% of patients, respectively. Subjects with -ve immunoreactivity for CCD1, and +ve immunoreactivity for MDM2 and gamma-catenin had significantly better survival than subjects with the opposite immunoreactive pattern. KAPLAN-meier survival curves confirmed this association.


CONCLUSIONS
The data indicate that expression of CCD1, MDM2, and gamma-catenin might serve as potential prognostic markers for BSCC in areca-using patients.
Liu
Chung-Ji
CJ
Department of Dentistry, Mackay Memorial Hospital, Taiwan, ROC.
Chang
Kuo-Wei
KW
Chao
Shou-Yee
SY
Kwan
Po-Cheung
PC
Chang
Shun-Min
SM
Yen
Rui-Yin
RY
Wang
Chun-Yu
CY
Wong
Yong-Kie
YK
D000328:Adult; D001114:Areca / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000032:analysis / Q000096:biosynthesis*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000209:etiology / Q000378:metabolism* / Q000401:mortality; D019938:Cyclin D1 / Q000032:analysis / Q000096:biosynthesis*; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000032:analysis / Q000096:biosynthesis; D003598:Cytoskeletal Proteins / Q000032:analysis / Q000096:biosynthesis*; D051180:Desmoplakins; D006651:Histocytochemistry; D006801:Humans; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000737:chemistry / Q000209:etiology / Q000378:metabolism* / Q000401:mortality; D009363:Neoplasm Proteins / Q000032:analysis / Q000096:biosynthesis*; D009687:Nuclear Proteins / Q000032:analysis / Q000096:biosynthesis*; D011379:Prognosis; D016016:Proportional Hazards Models; D011518:Proto-Oncogene Proteins / Q000032:analysis / Q000096:biosynthesis*; D051736:Proto-Oncogene Proteins c-mdm2; D016160:Retinoblastoma Protein / Q000032:analysis / Q000096:biosynthesis; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000096:biosynthesis; D051185:gamma Catenin
D014408:Biomarkers, Tumor; C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D003598:Cytoskeletal Proteins; D051180:Desmoplakins; C495292:JUP protein, human; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016160:Retinoblastoma Protein; D016159:Tumor Suppressor Protein p53; D051185:gamma Catenin; D019938:Cyclin D1; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2